Thrivent Financial for Lutherans Grows Position in Haemonetics Co. (NYSE:HAE)

Thrivent Financial for Lutherans raised its holdings in Haemonetics Co. (NYSE:HAE) by 6,573.6% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 849,350 shares of the medical instruments supplier’s stock after acquiring an additional 836,623 shares during the quarter. Thrivent Financial for Lutherans owned 1.67% of Haemonetics worth $70,267,000 as of its most recent filing with the SEC.

Several other institutional investors also recently made changes to their positions in the stock. TFO Wealth Partners LLC lifted its stake in shares of Haemonetics by 29,450.0% in the fourth quarter. TFO Wealth Partners LLC now owns 591 shares of the medical instruments supplier’s stock valued at $51,000 after purchasing an additional 589 shares during the period. Covestor Ltd lifted its position in shares of Haemonetics by 184.8% during the 1st quarter. Covestor Ltd now owns 675 shares of the medical instruments supplier’s stock valued at $58,000 after acquiring an additional 438 shares during the period. Daiwa Securities Group Inc. purchased a new stake in shares of Haemonetics during the 2nd quarter worth approximately $82,000. Canada Pension Plan Investment Board acquired a new stake in shares of Haemonetics in the 2nd quarter worth approximately $83,000. Finally, EntryPoint Capital LLC acquired a new stake in shares of Haemonetics in the 1st quarter worth approximately $86,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, EVP Anila Lingamneni sold 2,136 shares of the stock in a transaction dated Thursday, July 11th. The stock was sold at an average price of $90.00, for a total transaction of $192,240.00. Following the transaction, the executive vice president now directly owns 21,410 shares in the company, valued at $1,926,900. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, EVP Anila Lingamneni sold 2,136 shares of the company’s stock in a transaction that occurred on Thursday, July 11th. The shares were sold at an average price of $90.00, for a total transaction of $192,240.00. Following the completion of the transaction, the executive vice president now owns 21,410 shares of the company’s stock, valued at $1,926,900. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Stewart W. Strong sold 4,312 shares of the stock in a transaction that occurred on Friday, July 26th. The stock was sold at an average price of $91.15, for a total transaction of $393,038.80. Following the transaction, the insider now directly owns 18,196 shares in the company, valued at approximately $1,658,565.40. The disclosure for this sale can be found here. Company insiders own 1.80% of the company’s stock.

Haemonetics Price Performance

NYSE:HAE opened at $74.83 on Friday. Haemonetics Co. has a 12-month low of $70.74 and a 12-month high of $97.97. The firm has a market cap of $3.81 billion, a price-to-earnings ratio of 32.68, a price-to-earnings-growth ratio of 1.32 and a beta of 0.30. The company’s 50-day moving average is $80.21 and its two-hundred day moving average is $84.00. The company has a current ratio of 3.76, a quick ratio of 2.33 and a debt-to-equity ratio of 1.35.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.03 by ($0.01). The firm had revenue of $336.17 million for the quarter, compared to analysts’ expectations of $335.08 million. Haemonetics had a net margin of 8.61% and a return on equity of 21.86%. The business’s quarterly revenue was up 8.0% on a year-over-year basis. During the same period in the previous year, the company posted $1.05 EPS. Research analysts expect that Haemonetics Co. will post 4.58 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Needham & Company LLC raised Haemonetics from a “hold” rating to a “buy” rating and set a $112.00 price objective for the company in a report on Wednesday, June 12th. Barrington Research boosted their price objective on shares of Haemonetics from $107.00 to $108.00 and gave the stock an “outperform” rating in a research report on Friday, August 9th. BTIG Research initiated coverage on shares of Haemonetics in a research note on Tuesday, September 10th. They issued a “buy” rating and a $112.00 price objective on the stock. CL King initiated coverage on shares of Haemonetics in a research report on Friday, September 13th. They set a “buy” rating and a $116.00 target price for the company. Finally, Citigroup lowered their price target on shares of Haemonetics from $94.00 to $85.00 and set a “neutral” rating on the stock in a research report on Thursday, August 22nd. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, Haemonetics presently has an average rating of “Moderate Buy” and an average price target of $106.14.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.